Back to Peptides
LongevityLow Risk

ARA-290

Also known as: Cibinetide, Innate Repair Receptor agonist

Half-life:
~3 hours

Administration Routes

subcutaneous injectionintravenous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

A modified erythropoietin peptide that activates tissue repair pathways without stimulating red blood cell production. Strong evidence for neuropathic pain and sarcoidosis.

Primary Research Areas

  • neuropathic pain relief
  • tissue repair
  • anti-inflammatory
  • metabolic improvement

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyInvestigational

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find ARA-290